Table A4.
CIPN Rates in Taxane- Versus Non–Taxane-Treated Patients
| Grades 2-4 Neuropathy | Grade 3-4 Neuropathy | |||||
|---|---|---|---|---|---|---|
| No, No. (%) | Yes, No. (%) | P* | No, No. (%) | Yes, No. (%) | P* | |
| Diabetes with chronic complications | ||||||
| Taxane | 82 (75) | 28 (25) | 97 (88) | 13 (12) | ||
| No taxane | 12 (100) | 0 (0) | .05 | 12 (6) | 0 (0) | .21 |
| Diabetes with or without chronic complications | ||||||
| Taxane | 286 (78) | 82 (22) | 328 (89) | 40 (11) | ||
| No taxane | 47 (100) | 0 (0) | < .001 | 47 (100) | 0 (0) | .02 |
| Autoimmune diseases† | ||||||
| Taxane | 70 (89) | 9 (11) | 76 (96) | 3 (4) | ||
| No taxane | 5 (100) | 0 (0) | .42 | 5 (100) | 0 (0) | .66 |
Abbreviation: CIPN, chemotherapy-induced peripheral neuropathy.
*
P value from χ2 test.
†
Autoimmune diseases include Sjögren’s syndrome, lupus, rheumatoid arthritis, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, vasculitis, and giant cell arteritis.